Related Experiment Video
Updated: Nov 16, 2025

A Volumetric Method for Quantification of Cerebral Vasospasm in a Murine Model of Subarachnoid Hemorrhage
Published on: July 28, 2018
Role of Cilostazol in Prevention of Vasospasm After Aneurysmal Subarachnoid Hemorrhage-A Systematic Review,
Sandeep Bohara1, Kanwaljeet Garg1, Preet Mohinder Singh Rajpal2
1Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India.
Insights
Cilostazol effectively reduces symptomatic vasospasm, new-onset infarcts, and angiographic vasospasm following aneurysmal subarachnoid hemorrhage (aSAH). This meta-analysis confirms its benefit in preventing poor outcomes after aSAH.
Area of Science:
- Neurology
- Pharmacology
Background:
- Cerebral vasospasm is a frequent complication after aneurysmal subarachnoid hemorrhage (aSAH), leading to delayed cerebral ischemia.
- Various pharmacological agents have been investigated to prevent or treat cerebral vasospasm and its consequences.
Purpose of the Study:
- To evaluate the efficacy of cilostazol, a phosphodiesterase 3 inhibitor, in mitigating cerebral vasospasm and delayed cerebral ischemia post-aSAH.
- To perform a meta-analysis and trial sequential analysis to ascertain the effect of cilostazol on cerebral vasospasm after aSAH.
Main Methods:
- A systematic literature search identified eligible randomized controlled trials.
- Meta-analysis and trial sequential analysis were conducted on the selected studies.
Main Results:
- Four randomized controlled trials involving 454 articles were analyzed.
- Cilostazol significantly reduced symptomatic vasospasm (OR 0.35), new-onset infarct (OR 0.38), and angiographic vasospasm (OR 0.49).
- The drug also decreased the risk of unfavorable outcomes (RR 0.52).
Conclusions:
- Cilostazol administration post-aSAH is associated with decreased prevalence of symptomatic vasospasm, new-onset infarct, and angiographic vasospasm.
- Trial sequential analysis confirmed the robustness of these findings.
- Further multi-geographic studies are recommended to generalize these results.
Objective:
Cerebral vasospasm is a common complication after aneurysmal subarachnoid hemorrhage (aSAH). Many drugs have been tried to mitigate cerebral vasospasm and delayed cerebral ischemia. Cilostazol, a selective inhibitor of phosphodiesterase 3, is a promising agent in preventing cerebral vasospasm and delayed cerebral ischemia after aSAH. The objective of this article was to ascertain the effect of cilostazol on cerebral vasospasm after aSAH by performing meta-analysis and trial sequential analysis.
Methods:
A systematic search of the literature was performed, and all the eligible randomized controlled trials were included in the meta-analysis and trial sequential analysis.
Results:
A total of 454 articles were identified using the search criteria. Six articles were selected for systematic review and the 4 randomized controlled trials were included in the meta-analysis. The pooled odds ratio for symptomatic vasospasm, new-onset infarct, and angiographic vasospasm was 0.35 (95% confidence interval [CI], 0.21-0.59; P < 0.0001), 0.38 (95% CI, 0.21-0.66; P = 0.0007) and 0.49 (95% CI, 0.31-0.80; P = 0.004), respectively. The pooled risk ratio for unfavorable outcome was 0.52 (95% CI, 0.37-0.74; P = 0.0003).
Conclusions:
Cilostazol decreases the prevalence of symptomatic vasospasm, new-onset infarct, and angiographic vasospasm when administered after aSAH. Trial sequential analysis increased the precision of our results because the defined thresholds of effect were met by the available studies. However, further studies involving patients from other geographic areas are required to confirm the generalization of the results.
More Related Videos
10:41Analysis of Cerebral Vasospasm in a Murine Model of Subarachnoid Hemorrhage with High Frequency Transcranial Duplex Ultrasound
Published on: June 3, 2021
07:03A Low Mortality Rat Model to Assess Delayed Cerebral Vasospasm After Experimental Subarachnoid Hemorrhage
Published on: January 17, 2013
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Aneurysm III: Interprofessional Care
Vascular Spasm
Aneurysm IV: Nursing Management
Venous Thrombosis III: Interprofessional Care